420 LEXINGTON AVE,, NEW YORK, NY
Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Ships First International Order of LYMPHIR™ to Europe
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Other Events
Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Reports Fiscal Year 2025 Financial Results and Provides Business Update
Q1
Q4
FY 2024
Q2
Amended Annual Report
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Preliminary Information Statement
Definitive Information Statement
Definitive Proxy Statement
Definitive Additional Proxy Soliciting Materials
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence